v3.26.3
Acquisitions - Summary of Initial Consideration Recognized and Fair Value of Assets Acquired (Details) - Mantle Therapeutics Inc.
$ in Thousands
Sep. 29, 2026
USD ($)
Business Combination [Line Items]  
Initial cash consideration paid $ 5,009
Final cash consideration payable (receivable), estimated (10)
Net liabilities assumed, estimated 321
Fair value of shares of the Company's common stock issued 2,165
Fair value of Contingent Consideration Liabilities 1,267
Transaction costs, estimated 1,122
Consideration paid 9,874
Assets acquired:  
Total assets acquired 9,874
IPR&D Assets  
Assets acquired:  
Acquired in-process research and development $ 9,874